TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01772823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3MV
Description: Many Men, Many Voices (3MV) is based on Social Cognitive Theory and the Transtheoretical Model of Behavior Change. 3MV is a group-level intervention that addresses behavioral and social determinants and other factors influencing the HIV/sexually transmitted infection (STI) risk and protective behaviors of Men having sex with men (MSM) of color. The other factors include cultural, social and religious norms, racial identity and degree of connectedness to communities, HIV/STI interactions, sexual relationship dynamics, and the social influences of racism and homophobia.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCC
Description: Personalized Cognitive Counseling (PCC) is based on the Model of Relapse Prevention and Gold's Self-Appraisal of Risk Behavior. PCC is a 1-hour, single-session, individual level intervention administered by a trained counselor in a clinic setting. Counselors ask the client to recall and describe in as much detail, a recent encounter of unprotected anal sex with another man of unknown or sero-discordant HIV status. The client then identifies and expresses thoughts, feelings, or attitudes that might have led to the high-risk behavior. The client and counselor examine and identify thoughts that may have led the client to decide to engage in high transmission risk sex. The client and counselor agree on strategies that can be used to deal with similar situations in the future.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir (FTC/TDF (Truvada®))
Description: All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir (FTC/TDF (Truvada®))
Description: All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
Study: NCT04640818

Intervention type: DRUG
Intervention: Cladribine Oral Tablet
Description: Treatment according to the label and medical prescription

Intervention type: DRUG
Intervention: Rituximab
Description: Treatment according to the label and medical prescription

Intervention type: DRUG
Intervention: Ocrelizumab
Description: Treatment according to the label and medical prescription
Study: NCT04240028

Intervention type: OTHER
Intervention: Data Collection
Description: The NuAge study has been designed to investigate nutrition as a determinant of successful aging in older men and women in Quebec. This study is based on a population-based observational cohort design that initially recruited healthy community-dwellers with age ranged from 67 to 82 years (51.8% women) between January 2004 and April 2005. All participants lived in the areas of Montreal, Laval, and Sherbrooke in the Province of Quebec, Canada. After recruitment, they have been followed for 3 years with one clinical follow-up assessment each year (i.e.; 4 data collection time). A previous analysis performed on the NuAge study database has shown a significant decline of physical and cognitive performances with time (respectively an average of 10% and 2%), participants with lower physical performance showing lower cognitive performance.

Intervention type: OTHER
Intervention: Data Collection
Description: The NuAge study has been designed to investigate nutrition as a determinant of successful aging in older men and women in Quebec. This study is based on a population-based observational cohort design that initially recruited healthy community-dwellers with age ranged from 67 to 82 years (51.8% women) between January 2004 and April 2005. All participants lived in the areas of Montreal, Laval, and Sherbrooke in the Province of Quebec, Canada. After recruitment, they have been followed for 3 years with one clinical follow-up assessment each year (i.e.; 4 data collection time). A previous analysis performed on the NuAge study database has shown a significant decline of physical and cognitive performances with time (respectively an average of 10% and 2%), participants with lower physical performance showing lower cognitive performance.

Intervention type: OTHER
Intervention: Data Collection
Description: The NuAge study has been designed to investigate nutrition as a determinant of successful aging in older men and women in Quebec. This study is based on a population-based observational cohort design that initially recruited healthy community-dwellers with age ranged from 67 to 82 years (51.8% women) between January 2004 and April 2005. All participants lived in the areas of Montreal, Laval, and Sherbrooke in the Province of Quebec, Canada. After recruitment, they have been followed for 3 years with one clinical follow-up assessment each year (i.e.; 4 data collection time). A previous analysis performed on the NuAge study database has shown a significant decline of physical and cognitive performances with time (respectively an average of 10% and 2%), participants with lower physical performance showing lower cognitive performance.
Study: NCT03100955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin, etoposide
Description: The recommended regimen is cisplatin plus etoposide. cisplatin 75 mg/m2 iv on day 1, etoposide 120 mg/m2 iv on day 1-3, 3 weeks a cycle, total for 6 cycles is allowed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin, etoposide, apatinib
Description: Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatin and etoposide. Numbers of cycles 6. In addition to this, subjects will receive VEGF-TKI apatinib oral daily after chemotherapy treatment. Apatinib 500mg oral, once a day, until disease progression or death or un-tolerated toxicites.
Study: NCT04423172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the new tissue containment system
Description: Using the new tissue containment system during Laparoscopic hysterectomy. The divice is a soft specimen bag in which the uterus tissue is sealed and quickly morcellation and removed through vagina. The divice is named the new tissue containment system.
Study: NCT02656849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 1000394
Study: NCT03468179

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oatmeal
Description: Subjects will be fed a calculated serving of oatmeal.
Study: NCT02386553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nusinersen
Description: Solution for intrathecal injection
Study: NCT01186731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome Entrapped Docetaxel (LE-DT)
Description: 110 mg/m2 (IV)in vein on day 1 of each 21 day cycle , 6 cycles, until progression or unacceptable toxicity
Study: NCT01409122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg sodium nitrite inhalation solution
Description: 15 mg sodium nitrite inhalation solution Q8H

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90 mg sodium nitrite inhalation solution
Description: 90 mg sodium nitrite inhalation solution Q8H

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90 mg sodium nitrite inhalation solution
Description: 90 mg sodium nitrite inhalation solution Q8H

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90 mg sodium nitrite inhalation solution
Description: 90 mg sodium nitrite inhalation solution Q8H

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 45 mg sodium nitrite inhalation solution
Description: 45 mg sodium nitrite inhalation solution Q8H

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120 mg sodium nitrite inhalation solution
Description: 120 mg sodium nitrite inhalation solution or placebo Q8H

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25% MTD sodium nitrite inhalation solution
Description: Multiple oral doses of 20 mg sildenafil will be administered open-label Q8H to a single cohort of eight subjects on Days 1 to 6. A single dose of sodium nitrite inhalation solution equal to 25% of the maximum tolerated dose (MTD) identified in Part A (or placebo) will be administered on Day 4, a single dose equal to 50% of the MTD (or placebo) will be administered on Day 5, and a single dose equal to 100% of the MTD (or placebo) will be administered on Day 6.
Study: NCT02470923

Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine replacement therapy

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intensive counseling

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Medical advice
Study: NCT03543605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROA Experimental
Description: PROA Control plus clinical advice

Intervention type: OTHER
Group type: OTHER
Intervention: PROA Control
Description: PROA Control
Study: NCT01339624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FENTANYL
Description: FENTANYL CITRATE, NASAL, 3 GAMMA/KG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine AND morphine
Description: morphine 5 MG diluted in saline solution 100 ml followed by 2-ml ampoule of ketorolac 30 MG in saline solution 100 ml was infused:
Study: NCT03752242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMX-010 0.3%
Description: Safety and efficacy of BMX-010 in topical treatment of acne.
Study: NCT01387815

Intervention type: BIOLOGICAL
Intervention: Adalimumab
Description: Adalimumab administered by subcutaneous injection.
Study: NCT03234998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: motor-cognitive dual-task training
Description: Participants in the motor-cognitive dual-task training group will will receive an individually-progressed program of dual-task balance/gait training aimed at improving standing balance, sit-to-stand, and walking abilities under motor-cognitive dual-task conditions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cognitive dual-task training
Description: Participants in the cognitive dual-task training group will perform only cognitive tasks (verbal fluency tasks, calculation tasks, and visual discrimination tasks) concurrently with the balance/gait tasks.
Study: NCT00568698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match hydroxyurea
Study: NCT02028286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS001
Study: NCT03177109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% fluoride varnish
Description: Applied topically as a coating at single point in time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 8% arginine containing paste
Description: Applied topically as a coating at single point in time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Self-adhesive resin
Description: Applied topically as a coating at single point in time and light cured for 20 seconds
Study: NCT02717741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafetinib
Study: NCT02149524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin (trastuzuamb)
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB3 (proposed trastuzumab biosimilar)
Description: Intravenous administration
Study: NCT01172808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo that represents comparator
Study: NCT03306004

Intervention type: OTHER
Intervention: Questionare

Intervention type: OTHER
Intervention: Questionare
Study: NCT05574751

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Titanium tacker
Description: Mesh fixation with Titanium tacker

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polypropylene 0
Description: Mesh was sutured and fixed with polypropylene 0
Study: NCT00590226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Detemir + aspart insulin before meals
Description: Detemir insulin SQ once daily + aspart insulin SQ before meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin + regular insulin
Description: NPH insulin SQ + regular insulin SQ before breakfast and dinner
Study: NCT00635401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 0.5 mg BID for 7 weeks
Study: NCT01172808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium Respimat® low dose
Description: IMP

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo that represents comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo that represents comparator
Study: NCT02324777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis sativa L. subsp. indica, variety indica blends of flowering heads that have been air-dried, milled, destemmed and fine ground, stored in glass vials with aluminum caps in 100 mg dose size.
Study: NCT01172808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium Respimat® high dose
Description: IMP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mcg salmeterol HFA MDI
Description: Active comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo that represents BI drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo that represents BI drug
Study: NCT00316914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium gluconate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesium sulfate
Description: Given IV

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given IV
Study: NCT03840408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation
Description: Patients will be treated with mitochondria-targeted system therapy and radiofrequency ablation in the primary tumor sites

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Patients will be treated with surgery
Study: NCT04640038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur hexafluoride lipid-type A microspheres
Description: Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg. Two bolus injections will be performed to evaluate for dynamic bowel perfusion and several 2-minute cine clips as well as static images will be acquired during the exam.
Study: NCT04046822

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide 6 MG/ML [Saxenda]
Description: Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
Study: NCT02703376

Intervention type: DRUG
Group type: OTHER
Intervention: Oral Prednisone
Description: Intakes of Oral Prednisone for 12 weeks after balloon dilations
Study: NCT01990768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 gram Tranexamic Acid (TXA)
Description: TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 grams TXA
Description: TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.
Study: NCT02324777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis sativa L. subsp. indica, variety indica blends of flowering heads that have been air-dried, milled, destemmed and fine ground, stored in glass vials with aluminum caps in 100 mg dose size.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis sativa L. subsp. indica, variety indica blends of flowering heads that have been air-dried, milled, destemmed and fine ground, stored in glass vials with aluminum caps in 100 mg dose size.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis sativa L. subsp. indica, variety indica blends of flowering heads that have been air-dried, milled, destemmed and fine ground, stored in glass vials with aluminum caps in 100 mg dose size.
Study: NCT01990768

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride injectable
Description: Loading dose of 0.9% Sodium Chloride solution given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival. No active drug is added to the solution.
Study: NCT01393106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib tablets administered orally
Study: NCT02226120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid
Study: NCT00300846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aripiprazole
Description: Tablets, Oral, 5 mg, 10 mg, 15 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional)
Study: NCT03497767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: All participants will receive a dose of Osimertinib 80mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: All participants will receive a dose of Osimertinib 80mg once daily

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS)
Description: Dose and fractionation depend on lesion size. All SRS must be completed within 21 days of randomisation and all lesions are to be treated within 7 days.
Study: NCT00559663

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Green tea
Description: The green tea group consumed first daily one liter of green tea infusate made of 4 bags left in boiling water during 3 minutes.~After a four week washout-time they were switched over to the dark chocolate treatment, which included consumption of 3.5 ounces 70% dark chocolate.~Blood was drawn before and after each intervention, to check platelet activity with flow cytometry, HDL, LDL and hsCRP Levels
Study: NCT02977247

Intervention type: OTHER
Intervention: Non-Interventional
Description: Only standard care procedures will be performed for clinical intervention and diagnostic purposes.

Intervention type: DEVICE
Intervention: Automated Whole Breast Ultrasound
Description: Bilateral breast ultrasound images will be captured, but not clinically evaluated for diagnostic purposes by a physician.
Study: NCT02518347

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FDS-Strawberry
Description: Natural frozen and dried strawberries

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo powder matched for carbohydrates and fiber in the strawberries
Study: NCT00666198

Intervention type: DRUG
Intervention: SILDENAFIL
Description: Revatio® Tablets 20 mg Dosage, Frequency: According to Japanese LPD, For oral use, the adult dose is 20 mg three times a day.~Duration: According to the protocol of A1481263, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 3 years after the first administration.
Study: NCT04266444

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exergaming in virtual environment
Description: The 10Cubes game (by I. Cikajlo) will be used. In the game, the motion of the hand, wrist and fingers is tracked by an infra-red camera (by LeapMotion, Inc.) and hand motion is reflected in the virtual environment. The software will run on a powerful computer with a 19 display. Each group will have the game set to a different level of difficulty.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exergaming in virtual environment
Description: The 10Cubes game (by I. Cikajlo) will be used. In the game, the motion of the hand, wrist and fingers is tracked by an infra-red camera (by LeapMotion, Inc.) and hand motion is reflected in the virtual environment. The software will run on a powerful computer with a 19 display. Each group will have the game set to a different level of difficulty.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exergaming in virtual environment
Description: The 10Cubes game (by I. Cikajlo) will be used. In the game, the motion of the hand, wrist and fingers is tracked by an infra-red camera (by LeapMotion, Inc.) and hand motion is reflected in the virtual environment. The software will run on a powerful computer with a 19 display. Each group will have the game set to a different level of difficulty.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exergaming in virtual environment
Description: The 10Cubes game (by I. Cikajlo) will be used. In the game, the motion of the hand, wrist and fingers is tracked by an infra-red camera (by LeapMotion, Inc.) and hand motion is reflected in the virtual environment. The software will run on a powerful computer with a 19 display. Each group will have the game set to a different level of difficulty.
Study: NCT02988349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate® Sensitive Pro-Relief® toothpaste
Description: Subjects will be instructed to brush their teeth twice daily for 3 min using Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colgate® Sensitive Pro-Relief® toothpaste
Description: Subjects will be instructed to brush their teeth twice daily for 3 min using Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks.
Study: NCT04347785

Intervention type: PROCEDURE
Intervention: carotid endarterectomy
Description: shunt

Intervention type: PROCEDURE
Intervention: carotid endarterectomy
Description: shunt
Study: NCT03643497

Intervention type: DRUG
Intervention: anti-infective drugs
Description: According to the models of population pharmacokinetics, the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children